ATR
AptarGroup, Inc.
ATR has the edge over NVO overall on the model score.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
ATR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
ATR's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ATR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $142 | — |
| Cheap | 24x | $100 | -29% |
| Fair | 32x | $131 | -7.7% |
| Current | 34x | $142 | — |
| Expensive | 35x | $145 | +2.1% |
Historical ranges are pointers, not guarantees.
ATR's PE is in its expensive range at 34x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ATR in the historical PE scenario, which offers more potential upside but is not a forecast.
ATR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
ATR has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ATR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.08 | +48% |
| Q3 2026 | $4.12 | -34% |
| Q2 2026 | $5.53 | -4.7% |
| Q1 2026 | $5.84 | +6.8% |
| Q4 2025 | $5.89 | +6.5% |
| Q3 2025 | $6.24 | +25% |
| Q2 2025 | $5.80 | +22% |
| Q1 2025 | $5.47 | +17% |
| Q4 2024 | $5.53 | +30% |
ATR's earnings per share have fallen from their peak: $4.12 over the past year, against $6.24 in late 2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ATR on earnings, with more consistent year-over-year improvement.
ATR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +6% |
| Q2 2026 | $1B | +6.3% |
| Q1 2026 | $982.9M | +11% |
| Q4 2025 | $962.7M | +14% |
| Q3 2025 | $961.1M | +5.7% |
| Q2 2025 | $966M | +6.1% |
| Q1 2025 | $887.3M | -3.1% |
| Q4 2024 | $848.1M | +1.1% |
ATR's revenue has grown year over year for six quarters in a row: $1B last quarter, up 6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1 points |
| Q2 2026 | 12% | -2.6 points |
| Q1 2026 | 11% | -1.8 points |
| Q4 2025 | 11% | -3.1 points |
| Q3 2025 | 14% | -1 points |
| Q2 2025 | 15% | +1.1 points |
| Q1 2025 | 13% | +0.5 points |
| Q4 2024 | 14% | +4.1 points |
ATR's operating margin was 13% last quarter, down 1 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ATR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ATR on profitability, with a higher operating margin.
ATR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $98.6M | -14% |
| Q2 2026 | $45.9M | -27% |
| Q1 2026 | $53.3M | +106% |
| Q4 2025 | $96.9M | -14% |
| Q3 2025 | $114.3M | -30% |
| Q2 2025 | $62.5M | -17% |
| Q1 2025 | $25.9M | +55% |
| Q4 2024 | $112.2M | -19% |
ATR's free cash flow has been positive every quarter for seven years: $295M over the past year, down 6.4% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ATR on cash flow, with more consistent year-over-year improvement.
ATR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -61K shares |
| 1 year | -3.7% | -2.5M shares |
| 3 years | -4.3% | -2.9M shares |
| 5 years | -5.4% | -3.7M shares |
| Available history | -3.1% | -2M shares |
ATR has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $30M |
| Q2 2026 | $50M |
| Q1 2026 | $100M |
| Q4 2025 | $175M |
| Q3 2025 | $40M |
| Q2 2025 | $70M |
| Q1 2025 | $80M |
| Q4 2024 | $37.3M |
ATR spent $355M buying back its own shares over the past year, up 56% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ATR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
ATR's net debt is about 1.5 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over ATR on leverage, with a lower net debt burden relative to earnings.
ATR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 78.5 | Neutral |
ATR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ATR PE vs Healthcare Sector
| Metric | ATR | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 33% above |
| PE % | 80 | 29 | 51 pts above |
ATR is trading at 34x earnings, a 33% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ATR on valuation relative to its sector.
ATR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 9.4% above |
| 20 week MA | $130.0 | 9% above |
| 50 week MA | $127.1 | 11% above |
| 100 week MA | $135.9 | 4.3% above |
| 200 week MA | $135.3 | 4.8% above |
ATR has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ATR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.0 | $135.7 | +18% |
| 2021 | $135.7 | $116.3 | -14% |
| 2022 | $116.3 | $110.0 | -5.4% |
| 2023 | $110.0 | $123.6 | +12% |
| 2024 | $123.6 | $158.2 | +28% |
| 2025 | $158.2 | $123.3 | -22% |
| 2026 YTD | $123.3 | $141.7 | +15% |
ATR has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.